Bavarian Nordic A/S (BVNRY)
USD 9.23
(-0.22%)
USD 9.23
(-0.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.33 Billion DKK | -212.5% |
| 2022 | 1.18 Billion DKK | 118.93% |
| 2021 | 540.77 Million DKK | 192.98% |
| 2020 | 184.57 Million DKK | -87.97% |
| 2019 | 1.53 Billion DKK | 303.97% |
| 2018 | 379.83 Million DKK | 218.14% |
| 2017 | 119.39 Million DKK | 114.53% |
| 2016 | -821.74 Million DKK | -141.14% |
| 2015 | -340.77 Million DKK | 6.17% |
| 2014 | -363.17 Million DKK | -36.29% |
| 2013 | -266.48 Million DKK | -0.88% |
| 2012 | -264.16 Million DKK | -52.74% |
| 2011 | -172.95 Million DKK | -8.1% |
| 2010 | -159.98 Million DKK | -522.66% |
| 2009 | 37.85 Million DKK | 106.64% |
| 2008 | -569.77 Million DKK | -5.72% |
| 2007 | -538.94 Million DKK | -642.48% |
| 2006 | 99.34 Million DKK | 393.31% |
| 2005 | -33.87 Million DKK | -132.86% |
| 2004 | 103.06 Million DKK | 151.76% |
| 2003 | -199.11 Million DKK | -112.91% |
| 2002 | -93.51 Million DKK | -245.43% |
| 2001 | -27.07 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -727.22 Million DKK | 45.4% |
| 2024 Q2 | -691.79 Million DKK | 4.87% |
| 2023 FY | -1.33 Billion DKK | -212.5% |
| 2023 Q3 | -926.09 Million DKK | -1061.38% |
| 2023 Q2 | 96.32 Million DKK | 117.89% |
| 2023 Q1 | -538.6 Million DKK | -145.49% |
| 2023 Q4 | -1.33 Billion DKK | -43.82% |
| 2022 Q1 | 571.66 Million DKK | 5.71% |
| 2022 FY | 1.18 Billion DKK | 118.93% |
| 2022 Q2 | 1.16 Billion DKK | 102.93% |
| 2022 Q4 | 1.18 Billion DKK | 45.96% |
| 2022 Q3 | 811.14 Million DKK | -30.08% |
| 2021 Q4 | 540.77 Million DKK | -8.44% |
| 2021 FY | 540.77 Million DKK | 192.98% |
| 2021 Q1 | 239.43 Million DKK | 29.72% |
| 2021 Q2 | 601.44 Million DKK | 151.19% |
| 2021 Q3 | 590.59 Million DKK | -1.8% |
| 2020 Q4 | 184.57 Million DKK | 318.44% |
| 2020 Q1 | -979.34 Million DKK | -163.83% |
| 2020 FY | 184.57 Million DKK | -87.97% |
| 2020 Q2 | 105.22 Million DKK | 110.74% |
| 2020 Q3 | -84.5 Million DKK | -180.3% |
| 2019 Q3 | 356.79 Million DKK | 1.72% |
| 2019 FY | 1.53 Billion DKK | 303.97% |
| 2019 Q1 | 328.34 Million DKK | -13.55% |
| 2019 Q2 | 350.75 Million DKK | 6.82% |
| 2019 Q4 | 1.53 Billion DKK | 330.05% |
| 2018 FY | 379.83 Million DKK | 218.14% |
| 2018 Q4 | 379.83 Million DKK | 25.06% |
| 2018 Q3 | 303.7 Million DKK | -40.4% |
| 2018 Q2 | 509.61 Million DKK | 40.81% |
| 2018 Q1 | 361.91 Million DKK | 203.14% |
| 2017 Q3 | -428.93 Million DKK | -31.03% |
| 2017 Q2 | -327.34 Million DKK | 66.39% |
| 2017 Q1 | -973.85 Million DKK | -18.51% |
| 2017 Q4 | 119.39 Million DKK | 127.83% |
| 2017 FY | 119.39 Million DKK | 114.53% |
| 2016 Q2 | -426.9 Million DKK | -180.49% |
| 2016 Q1 | -152.2 Million DKK | 55.34% |
| 2016 FY | -821.74 Million DKK | -141.14% |
| 2016 Q4 | -821.74 Million DKK | -364.74% |
| 2016 Q3 | -176.81 Million DKK | 58.58% |
| 2015 Q1 | -984.6 Million DKK | -171.11% |
| 2015 Q3 | -428.57 Million DKK | 9.01% |
| 2015 Q4 | -340.77 Million DKK | 20.49% |
| 2015 FY | -340.77 Million DKK | 6.17% |
| 2015 Q2 | -471 Million DKK | 52.16% |
| 2014 FY | -363.17 Million DKK | -36.29% |
| 2014 Q2 | -38.2 Million DKK | 74.36% |
| 2014 Q1 | -149 Million DKK | 44.09% |
| 2014 Q4 | -363.17 Million DKK | -430.19% |
| 2014 Q3 | -68.5 Million DKK | -79.32% |
| 2013 Q4 | -266.48 Million DKK | -306.85% |
| 2013 Q3 | -65.5 Million DKK | 68.63% |
| 2013 Q2 | -208.8 Million DKK | -311.02% |
| 2013 Q1 | -50.8 Million DKK | 80.77% |
| 2013 FY | -266.48 Million DKK | -0.88% |
| 2012 FY | -264.16 Million DKK | -52.74% |
| 2012 Q3 | -173.8 Million DKK | -27.98% |
| 2012 Q2 | -135.8 Million DKK | 14.27% |
| 2012 Q1 | -158.4 Million DKK | 8.41% |
| 2012 Q4 | -264.16 Million DKK | -51.99% |
| 2011 Q3 | 174 Million DKK | 587.75% |
| 2011 Q4 | -172.95 Million DKK | -199.4% |
| 2011 FY | -172.95 Million DKK | -8.1% |
| 2011 Q2 | 25.3 Million DKK | -64.62% |
| 2011 Q1 | 71.5 Million DKK | 144.69% |
| 2010 Q3 | 11.2 Million DKK | -32.12% |
| 2010 Q4 | -159.98 Million DKK | -1528.45% |
| 2010 FY | -159.98 Million DKK | -522.66% |
| 2010 Q1 | -86.1 Million DKK | -327.46% |
| 2010 Q2 | 16.5 Million DKK | 119.16% |
| 2009 Q4 | 37.85 Million DKK | 0.0% |
| 2009 FY | 37.85 Million DKK | 106.64% |
| 2008 FY | -569.77 Million DKK | -5.72% |
| 2007 FY | -538.94 Million DKK | -642.48% |
| 2006 FY | 99.34 Million DKK | 393.31% |
| 2005 FY | -33.87 Million DKK | -132.86% |
| 2004 FY | 103.06 Million DKK | 151.76% |
| 2003 FY | -199.11 Million DKK | -112.91% |
| 2002 FY | -93.51 Million DKK | -245.43% |
| 2001 FY | -27.07 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 8549.737% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 32443.959% |
| SQZ Biotechnologies Company | -36.23 Million USD | -3575.512% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 3212.5% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -21026.607% |
| Mesoblast Limited | 55.85 Million USD | 2484.486% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 143753.161% |
| Genus plc | 190.6 Million USD | 798.81% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 59672.097% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 109824.456% |
| Marizyme, Inc. | 18.56 Million USD | 7272.868% |
| ContraFect Corporation | -6.02 Million USD | -22003.087% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 195972.353% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 989361.655% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 115375.971% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 59502.034% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 24308.6% |
| MultiCell Technologies, Inc. | 90.04 USD | 1479267092.448% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -181367.564% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 10388.367% |
| EV Biologics, Inc. | 1.36 Million USD | 97465.514% |
| Q BioMed Inc. | 4.06 Million USD | 32906.142% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 4459.272% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 214111.736% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 132273.35% |
| Biomind Labs Inc. | 711.4 Thousand USD | 187326.35% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 1313.009% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 10500.364% |
| Skye Bioscience, Inc. | -5.72 Million USD | -23179.871% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 154932.425% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 952813.799% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 23680.821% |
| IMV Inc. | 7.67 Million USD | 17464.296% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 6704343.217% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 60587.897% |
| GB Sciences, Inc. | 1.74 Million USD | 76327.311% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -724611.08% |
| HST Global, Inc. | 96.79 Thousand USD | 1376162.319% |
| CSL Limited | 10.52 Billion USD | 112.654% |
| Halberd Corporation | 144.72 Thousand USD | 920444.663% |
| Enzolytics Inc. | 981.65 Thousand USD | 135782.153% |
| Resverlogix Corp. | 6.45 Million USD | 20746.907% |
| Affymax, Inc. | -5.59 Million USD | -23697.249% |
| SYBLEU INC | 473.71 Thousand USD | 281267.962% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -197783.489% |
| argenx SE | -2.02 Billion USD | 34.35% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 3166.565% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -2733.175% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 49273.914% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -14967.254% |
| AVAX Technologies, Inc. | -5.9 Million USD | -22462.854% |
| Zenith Capital Corp. | 10.06 Thousand USD | 13234718.442% |
| Genscript Biotech Corporation | -1.06 Billion USD | -25.496% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 664630.614% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 55922.004% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 809740.81% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 2299.877% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 66716.852% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -51725.503% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 370379.392% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 6669.008% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -7271064.974% |
| BioStem Technologies, Inc. | 4.47 Million USD | 29883.737% |
| ONE Bio Corp. | 9.04 Million USD | 14833.704% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 661916.411% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -101674098.473% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 645988.554% |
| Agentix Corp. | 37.63 Thousand USD | 3539554.173% |
| LadRx Corporation | -2.03 Million USD | -65303.991% |
| Cell Source, Inc. | 9.23 Million USD | 14527.385% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -6526419.012% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 209797.922% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 209797.922% |
| NovAccess Global Inc. | 2.17 Million USD | 61240.849% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 18936.618% |
| Itoco Inc. | 228.3 Thousand USD | 583500.276% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 979540.984% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 26969.72% |
| Kadimastem Ltd | -253.1 Thousand USD | -526143.175% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 331550.868% |
| CytoDyn Inc. | 20.26 Million USD | 6673.547% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -205862651.159% |
| Mobile Lads Corp. | 484.23 Thousand USD | 275160.715% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -14370671.897% |
| Qrons Inc. | 351.42 Thousand USD | 379106.735% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 17384.345% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -533483.847% |
| Rebus Holdings, Inc. | 305 Thousand USD | 436799.016% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 29983.9% |
| International Stem Cell Corporation | 2.59 Million USD | 51525.946% |
| Bioxytran, Inc. | 1.89 Million USD | 70241.776% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 2134161.814% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 61172.585% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 38886.605% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 15672.688% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 172494.503% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -106454.56% |
| Neutra Corp. | 52.18 Thousand USD | 2552329.482% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -53412.736% |
| PureTech Health plc | -167.19 Million USD | -696.624% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -543749.935% |
| IXICO plc | -4.44 Million USD | -29867.509% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 10175.891% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 2528.273% |
| CSL Limited | 10.52 Billion USD | 112.654% |
| Cellectis S.A. | -43.81 Million USD | -2939.631% |